Physician profile
Nancy L Shupe
NPI 1033146881
$992.51
in general payments reported to CMS, 2019-2025
22 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.63 · 2020: $84.74 · 2021: $147 · 2022: $136 · 2023: $257 · 2024: $119 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $589.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $148.45 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $135.52 | 2019-2023 | Vraylar, Qulipta, Ubrelvy |
| Vanda Pharmaceuticals INC. | $132.10 | 2024-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $86.61 | 2020-2023 | Mounjaro |
| Novo Nordisk INC | $86.17 | 2020-2025 | Ozempic, Rybelsus |
| Amgen INC. | $64.09 | 2021-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $46.83 | 2020-2023 | Trelegy Ellipta |
| Pfizer INC. | $41.13 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $28.81 | 2021 | |
| Neurocrine Biosciences, INC. | $26.00 | 2024 | Ingrezza |
| Allergan, INC. | $22.20 | 2020 | |
| Janssen Pharmaceuticals, INC | $21.31 | 2025 | Spravato |
| Merck Sharp & Dohme LLC | $19.54 | 2020 | |
| Amarin Pharma, INC. | $18.54 | 2021 | |
| Axsome Therapeutics, INC. | $17.07 | 2025 | Sunosi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $17.01 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.69 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $14.47 | 2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $14.44 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.66 | 2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $12.65 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Shupe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.